WEST Search History

DATE: Monday, June 17, 2002

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L3	(phospholipid$ or lecithin) adj10 (enteric$)	6	L3
L2	(phospholipid$ or lecithin) adj5 (enteric$)	2	L2
L1	(phospholipid$ or lecithin) same (enteric$)	168	L1

END OF SEARCH HISTORY

WEST

Generate Collection Print

L1: Entry 16 of 168 File: USPT Feb 6, 2001

DOCUMENT-IDENTIFIER: US 6183466 B1
TITLE: Dosage form comprising a capsule

Detailed Description Paragraph Right (18):
Representative of capsules for use in dosage form 10 comprises: a gelatin capsule comprising 50 mg of concentrated ginseng extract formulated with sucrose, palm kernel oil, ascorbic acid, lecithin, natural flavorings, and coloring agents; a gelatin capsule comprising enteric coated pellets of erythromycin including hydroxypropylmethylcellulose and magnesium stearate; a capsule comprising 200 mg of ethchlorvynol blended with glycerin, methylparaben, and polyethylene glycol; a capsule comprising 200 mg of mexiletine hydrochloride formulated with collidal silicon dioxide, corn starch, sodium lauryl sulfate and benzyl alcohol; a capsule comprising 100 mg of phendimetrazine tartrate, silica gel, starch, sucrose and povidone; a capsule comprising 500 mg of cefadroxil monohydrate; a capsule comprising 500 mg of acetaminophen, deionized water, ethylene glycol monoethyl ether, lecithin and sodium propionate; a capsule comprising 25 mg of butalbital and 150 mg of acetaminophen; a capsule comprising fluoxetine hydrochloride, ethyl alcohol, benzoic acid, purified water and sucrose, a capsule comprising 50 mg of butalbital, 325 mg of acetaminophen, and 40 mg of caffeine; a capsule comprising 180 mg of diltiazen hydrochloride; a capsule comprising 37.5 mg of phentermine hydrochloride; a capsule comprising 300 mg of rantidine hydrochloride; and, capsule comprising 1,000 mg of microencapsulated potassium chloride. The dose of therapeautic drug in a capsule is 0.05 to 2 g, with individual capsules containing 25 ng, 1 mg, 5 mg, 125 mg, 250 mg, 500 mg, 750 mg, 1.5 g and the like doses.

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 6183466 B1

L3: Entry 1 of 6 File: USPT Feb 6, 2001

US-PAT-NO: 6183466
DOCUMENT-IDENTIFIER: US 6183466 B1

TITLE: Dosage form comprising a capsule

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wong; Patrick S. L.	Burlingame	CA		
Theeuwes; Felix	Los Altos Hills	CA		
Ferrari; Vincent J.	Foster City	CA		
Dong; Liang C.	Sunnyvale	CA		

US-CL-CURRENT: 604/892.1; 424/451, 424/452, 424/453

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 2. Document ID: US 6177103 B1

L3: Entry 2 of 6 File: USPT Jan 23, 2001

US-PAT-NO: 6177103
DOCUMENT-IDENTIFIER: US 6177103 B1

TITLE: Processes to generate submicron particles of water-insoluble compounds

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pace; Gary W.	Raleigh	NC		
Vachon; Michael G.	Quebec			CAX
Mishra; Awadhesh K.	Quebec			CAX
Henrikson; Inge B.	Stavanger			NOX
Krukonis; Val	Lexington	MA		

US-CL-CURRENT: 424/489

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 3. Document ID: US 6039992 A

L3: Entry 3 of 6 File: USPT Mar 21, 2000

US-PAT-NO: 6039992
DOCUMENT-IDENTIFIER: US 6039992 A

TITLE: Method for the broad spectrum prevention and removal of microbial contamination of food products by quaternary ammonium compounds

DATE-ISSUED: March 21, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Compadre; Cesar	Little Rock	AR		
Breen; Philip	Little Rock	AR		
Salari; Hamid	Little Rock	AR		
Fifer; E. Kim	Little Rock	AR		
Lattin; Danny L.	Brookings	SD		
Slavik; Michael	Springdale	AR		
Li; Yanbin	Fatettville	AR		
O'Brien; Timothy	Little Rock	AR		

US-CL-CURRENT: 426/332; 426/335

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 5855940 A

L3: Entry 4 of 6 File: USPT Jan 5, 1999

US-PAT-NO: 5855940
DOCUMENT-IDENTIFIER: US 5855940 A

TITLE: Method for the broad spectrum prevention and removal of microbial contamination of poultry and meat products by quaternary ammonium compounds

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Compadre; Cesar	Little Rock	AR		
Breen; Philip	Little Rock	AR		
Salari; Hamid	Little Rock	AR		
Fifer; E. Kim	Little Rock	AR		
Lattin; Danny	Brookings	SD		
Slavik; Mike	Springdale	AR		
Li; Yanbin	Fayetteville	AR		

US-CL-CURRENT: 426/332; 426/335

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 5. Document ID: JP 63048227 A

L3: Entry 5 of 6 File: JPAB Feb 29, 1988

PUB-NO: JP363048227A
DOCUMENT-IDENTIFIER: JP 63048227 A
TITLE: SOLID PREPARATION FOR ORAL ADMINISTRATION COATED WITH PHOSPHOLIPID

PUBN-DATE: February 29, 1988

INVENTOR-INFORMATION:

NAME	COUNTRY
KIN, JUNJI	
SASAYA, HARUHIDE	
INABA, MITSUHARU	

INT-CL (IPC): A61K 47/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 6. Document ID: WO 9324113 A1, AU 9344003 A, US 5322697 A, EP 671907 A1, JP 07507546 W, EP 671907 A4, AU 684710 B

L3: Entry 6 of 6 File: DWPI Dec 9, 1993

DERWENT-ACC-NO: 1993-405399
DERWENT-WEEK: 200162
COPYRIGHT 2002 DERWENT INFORMATION LTD
TITLE: Controlling appetite in humans - comprises controlling intestinal absorption of satiety agent ingested by subject

INVENTOR: MEYER, J H

PRIORITY-DATA: 1992US-0889710 (May 28, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9324113 A1	December 9, 1993	E	032	A61K009/48
AU 9344003 A	December 30, 1993		000	A61K009/48
US 5322697 A	June 21, 1994		010	A61K009/54
EP 671907 A1	September 20, 1995	E	000	A61K009/48
JP 07507546 W	August 24, 1995		012	A61K009/00
EP 671907 A4	September 11, 1996		000	A61K009/48
AU 684710 B	January 8, 1998		000	A61K009/52

INT-CL (IPC): A61K 9/00; A61K 9/14; A61K 9/28; A61K 9/48; A61K 9/52; A61K 9/54; A61K 9/62; A61K 31/195; A61K 37/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
(phospholipid$ or lecithin) adj10 (enteric$)	6

Display Format: - Change Format

Previous Page Next Page

L1: Entry 110 of 168 File: USPT Feb 23, 1993

DOCUMENT-IDENTIFIER: US 5188836 A
TITLE: Sustained release formulations

Brief Summary Paragraph Right (8):
U.S. Pat. No. 4,832,958 to Baudier et al reveals a galenic form of prolonged release verapamil and its salts by mixing the drug with a wetting agent such as fatty acid esters, lecithin, sucrose, mannitol or sorbitol and then spheronizing or granulating the mixture into micro-granules. These are then coated with a microporous membrane comprised of a polymer such as Eudragit.RTM. E30D, (Rohm Pharma GmbH, Weiterstadt, West Germany), HPMC phthalate and other wetting agents, plasticizers and the like. The formulations are designed to withstand adverse environmental conditions during storage such as high temperatures. The formulation is enteric by nature and the drug does not become bioavailable until the system reaches the small intestine.

WEST

Generate Collection Print

L1: Entry 148 of 168 File: USPT Jul 18, 1989

DOCUMENT-IDENTIFIER: US 4849227 A
TITLE: Pharmaceutical compositions

Brief Summary Paragraph Right (30):
In another embodiment of this invention, insulin is mixed with a composition comprising at least one: lipid; amino acid; binder; enzyme inhibitors; anti-foaming agent; and water soluble material. The mixture is then coated with a lipid coating comprising triglycerides, phospholipids and cholesterol. The resultant product is then placed into a gel capsule and enteric coated.

Detailed Description Paragraph Right (73):
In this example oral insulin having a composition similar to that of the oral insulin composition of Example 1 was produced. The composition of Example 1 was varied by varying the lipid coating. The lipid coating was varied so that in addition to polyethylene glycol monostearate, phosphotidylephosphate (an amount sufficient to make a final concentration of 0.046.times.10.sup.-2 gm), phospholipids (an amount sufficient to to make a final concentration of 0.046.times.10.sup.-2 gm), and cholesterol (an amount sufficient to make a final concentration 2.628.times.10.sup.-4 mol) were added to the lipid coating materials. This lipid coating was coated onto the insulin and particles at a thickness of 0.3 microns. 240 mg of the oral insulin product was then packed by hand into a hard gel capsule. The gel capsule was coated with the enteric coating of Example 1.

L1: Entry 155 of 168 File: USPT Jun 25, 1985

DOCUMENT-IDENTIFIER: US 4525339 A
TITLE: Enteric coated oral dosage form

Detailed Description Paragraph Right (4):
The enteral formulations may take the form of solid or liquid formulations for oral application. Thus, the formulations may be in the form of enteric coated capsules, coated tablets or regular capsules or tablets containing an enterically microencapsulated mixture of enhancer and .beta.-lactam antibiotic or the two entities may be enteric coated separately. These formulations may, in addition, contain conventional pharmaceutical carriers and additives, especially viscosity-improving and/or structure- or matrix-forming additives which provide for an appropriate viscosity and physical structure. Suitable additives are, e.g., thickening agents, such as highly dispersed silicic acid (e.g., the commercial products "Aerosil") bentonites, colloidal clay, carboxymethyl celluloses, modified montmorillonites, such as alkyl ammonium salts of montmorillonites (e.g., the commercial products "Bentone") wherein the alkyl groups contain 16 to 18 carbon atoms, organic thickening and structure-forming agents, such as saturated higher fatty acids and alcohols containing, e.g., 12 to 20 carbon atoms, such as stearic or palmitic acid, stearic or cetylic alcohol, waxes like beeswax, synthetic esters of higher fatty acids and higher fatty alcohols, or spermaceti, monoglycerides of saturated or unsaturated high fatty acids, e.g., monoglycerides of stearic acid, palmitic acid or oleic acid, partial glycerides of fatty polyhydroxy acids (e.g., the commercial products "Softigen 701"), gelling agents, such as aluminum stearate, dispersing agents, such as anionic, nonionic and cationic surfactants, emulsifying agents, such as lecithin, and like salts. The compositions may further comprise pharmaceutical adjuvants, e.g., binders or lubricants for tableting, stabilizing agents, e.g., EDTA, antioxidants, e.g., ascorbic acid, flavoring agents, preservatives, e.g., methyl or propyl parabens and buffering agents, e.g., phosphates. Useful coloring agents include the acceptable FD & C dyes. Useful opacifiers include titanium dioxide.

L1: Entry 157 of 168 File: JPAB Aug 4, 1998

DOCUMENT-IDENTIFIER: JP 10203964 A
TITLE: NEW PREPARATION IMPROVING ORAL BIOLOGICAL UTILIZING ABILITY OF HARDLY ABSORBABLE MEDICINE

Abstract (2):
SOLUTION: This preparation for oral administration is obtained by mixing a medicine with a liposome containing a hydrogenated lecithin and cholesterol, drying the mixed medicine by distillation dehydrating or freeze drying to provide a powder, and forming the powder into a capsule or tablet treated with an enteric coating so that the content may be released after passing the stomach. The lipid used for obtaining the liposome is preferably a mixture of the cholesterol and a hydrogenated natural lecithin having <2g/100g iodide value. The medicine is an antibiotic such as gentamicin, an antivirus agent, an antitumor agent, etc. The enteric coating is preferably an acrylic resin, a cellulose derivative, etc.

WEST

5206219

Generate Collection Print

L1: Entry 164 of 168 File: DWPI Apr 27, 1993

DERWENT-ACC-NO: 1993-151742
DERWENT-WEEK: 199318

TITLE: Pharmaceutical enteric coated compsn. for oral administration to intestinal tract - comprises protease inhibitor and proteinaceous medicament e.g. erythropoietin, phospholipid, cholesterol, surfactant, and medium contg. poly:ol and lipid solvent